CELL-PENETRATING PEPTIDES NANO-CONJUGATED WITH METALLIC NANOPARTICLE FOR THE DEVELOPMENT OF THERAPEUTIC AND OR PROPHYLACTIC AGENTS AGAINST RESPIRATORY SYNCYTIAL VIRUS

Author:

Sharma Homa Nath

Abstract

Respiratory Syncytial Virus (RSV) is an enveloped, pleomorphic, often filamentous, cytoplasmic virus-containing non-segmented, negative-sense, single-stranded RNA associated with viral proteins, making up a nucleocapsid core that is enclosed within a lipid envelope. RSV causes about 7 % of deaths among infants and young children globally, which is the second-most cause of mortality in that age group after malaria. Despite the immense impact mounted by RSV in public health and the economy, there are no effective prophylactic and therapeutic agents to control and treat the disease caused by RSV. Currently, four RSV vaccines and a monoclonal antibody candidate, all using the stabilized pre-fusion (F) proteins, have shown promising results in healthy subjects and are in phase III clinical trial. Results from these trials are expected to be released soon. However, more than one type of vaccine and therapeutics are required to cover all populations at risk: younger children, older adults, pregnant women, and immunocompromised people. Search for more antiviral drugs and vaccines is going on, but due to the issues of cost, toxicity, resistance, bioavailability, and overall pharmacokinetic profile associated with prospective traditional drugs, studies on antiviral peptides can offer novel avenues in the field. In recent years, cell-penetrating peptides (CPPs) with 5-30 AAs in length have shown promising drug delivery potential, but antiviral property demonstrated by some CPPs is another exciting possibility in the drug discovery arena, since finding shorter anti-viral peptides is another priority to minimize the cost. Some of the metallic nanoparticles have shown antiviral properties themselves. If both cell-penetrating property and antiviral activity can be found in the same peptide, nano-conjugating CPP with or without other antiviral peptides can improve the stability and other therapeutic indices of such peptide so that it can possibly be developed as safe and effective therapeutic and or prophylactic tools to control RSV.

Publisher

Granthaalayah Publications and Printers

Subject

Ocean Engineering

Reference132 articles.

1. Akkarawongsa, R., Potocky, T. B., English, E. P., Gellman, S. H., & Brandt, C. R. (2008). Inhibition of Herpès Simplex Virus Type 1 Infection by Cationic Beta-Peptides. Antimicrobial Agents and Chemotherapy, 52(6), 2120-2129. https://doi.org/10.1128/AAC.01424-07.

2. Alghrair, Z. K., Fernig, D. G., & Ebrahimi, B. (2019). Enhanced Inhibition of Influenza Virus Infection by Peptide-Noble-Metal Nanoparticle Conjugates. Beilstein Journal of Nanotechnology, 10, 1038-1047. https://doi.org/10.3762/bjnano.10.104.

3. Andaloussi, S. E., Lehto, T., Mäger, I., Rosenthal-Aizman, K., Oprea, I. I., Simonson, O. E., Sork, H., Ezzat, K., Copolovici, D. M., Kurrikoff, K., Viola, J. R., Zaghloul, E. M., Sillard, R., Johansson, H. J., Said Hassane, F., Guterstam, P., Suhorutšenko, J., Moreno, P. M., Oskolkov, N., Langel, U. (2011). Design of a Peptide-Based Vector, PepFect6, for Efficient Delivery of siRNA in Cell Culture and Systemically in Vivo. Nucleic Acids Research, 39(9), 3972-3987. https://doi.org/10.1093/nar/gkq1299.

4. Battles, M. B., & McLellan, J. S. (2019). Respiratory Syncytial Virus Entry and How to Block it. Nature Reviews. Microbiology, 17(4), 233-245. https://doi.org/10.1038/s41579-019-0149-x.

5. Battles, M. B., Langedijk, J. P., Furmanova-Hollenstein, P., Chaiwatpongsakorn, S., Costello, H. M., Kwanten, L., Vranckx, L., Vink, P., Jaensch, S., Jonckers, T. H., Koul, A., Arnoult, E., Peeples, M. E., Roymans, D., & McLellan, J. S. (2016). Molecular Mechanism of Respiratory Syncytial Virus Fusion Inhibitors. Nature Chemical Biology, 12(2), 87-93. https://doi.org/10.1038/nchembio.1982.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3